CVRX INC (CVRX)
Health Care · medical devices · NASDAQ
CVRx commercializes Barostim, the first FDA-approved neuromodulation device that activates baroreceptors to treat severe heart failure in patients who fail traditional medications.
What CVRX INC does
CVRx is a commercial-stage medical device company developing and commercializing Barostim, an implantable neuromodulation device that delivers electrical pulses to baroreceptors in the carotid artery to treat heart failure with reduced ejection fraction (HFrEF). The device uses Baroreflex Activation Therapy (BAT) to modulate the autonomic nervous system and improve cardiovascular function in patients who have failed medical therapy. Barostim is FDA-approved in the U.S. and CE-marked in Europe, and the company is building a dedicated sales force and securing reimbursement coverage to drive adoption in hospitals and outpatient centers.
Themes: neuromodulation / cardiac, heart failure treatment, HFrEF / reduced ejection fraction, implantable medical devices, cardiovascular autonomic regulation, refractory hypertension indication
Fundamentals
- Price$2.84 as of 2026-08-21 close
- Market cap$76M as of 2026-08-21
- 1-year return-62.5% 2025-08-21 close $7.57 → 2026-08-21 close $2.84
- P/En/a negative earnings
- Net margin-89.2% as of 2026-08-24
- Gross margin+86.2% as of 2026-08-24
- ROE-120.8% as of 2026-08-24
- Debt / equity2.01 as of 2026-08-24
- Revenue growth (YoY)+11.7% as of 2026-08-24
- Revenue CAGR (3y)+36.1% SEC XBRL
- Beta0.70 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How CVRX compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CVRX INC looks technically
CVRX INC (CVRX) is trading 59.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 131 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 10 trading days ago. It is 74.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 59.1% below its 200-day average, the long-term trend line — a long-term downtrend | -59.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.68 | $4.68 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.94 | $6.94 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 3.24. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 131 trading days ago — a "death cross", a bearish long-term signal | 131 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 23.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 34, neither overbought (above 70) nor oversold (below 30) | 34.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($2.20 to $6.00) — its "stochastic" reading is 17 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 16.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $11.30 | $11.30 |
|---|---|---|
| From the 52-week high | it is 74.9% below its 52-week high (its highest price of the past year) | -74.9% |
| Above the 52-week low | it is 29.1% above its 52-week low (its lowest price of the past year) | +29.1% |
| Below the 52-week high | it is 74.9% below its highest point of the past year | 74.9% |
| Since a 20-day breakout | it made a new 20-day low about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day low about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $33.13 (set on 2023-12-29) | $33.13 |
| Given back of the 52-week move | over the past year its closes ranged ($2.37 to $10.81), and it has recovered only a small part of its fall from last year’s high — 6% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.59 to $7.86. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 5.6% |
| From the all-time high | it is 91.4% below its all-time high | -91.4% |
| Nearest price level | it is trading 76.5% below a resistance level at $5.01 — a price it turned at twice since 2026-05-13, most recently on 2026-07-01. Since 2024-08-21 it has 0 such levels below the current price and 15 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +76.5% |
| All-time low | its lowest closing price on record is $2.20 (set on 2026-08-10) | $2.20 |
| Above the all-time low | it is 29.1% above its all-time low | +29.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.406 between its high and its low — about 14.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.406 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.28 and $6.52 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.28 – $3.90 – $6.52 |
| Typical daily range (% of price) | its price moves about 14.3% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 14.3% |
| Stretch from the 200-day average | it is trading 10.1 daily ranges below its 200-day average price (59.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 10.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.69× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a hammer | 9 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 9 sessions ago |
| Since a bullish engulfing | 2 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.7% |
|---|---|---|
| Open gap | it gapped 49.3% below the previous close 10 sessions ago and has not traded back through the level it left behind at 5.94 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -49.3% |
| Gap filled | a 4.8% gap up opened on 2026-08-14 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 5 sessions ago |
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 45.2 percentage points (the stock lost 42.9% while the market gained 2.3%) | -45.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 56.3 percentage points (the stock lost 53.2% while the market gained 3.1%) | -56.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 64.6 percentage points (the stock lost 53.5% while the market gained 11.1%) | -64.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 83.0 percentage points (the stock lost 62.5% while the market gained 20.5%) | -83.0% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 48% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 35.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -47.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 43% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $5.00 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -43.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $2.62 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +8.5% |
Price levels it has turned at before
CVRX last closed at $2.84 on 2026-08-21. Since 2024-08-21 it has turned at 0 prices below its last close and 15 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.01 | Resistance | 76.5% above the last close | turned there twice · 2026-05-13 to 2026-07-01 |
| $5.86 | Resistance | 106.3% above the last close | turned there three times · 2025-04-08 to 2026-07-16 |
| $5.99 | Resistance | 110.8% above the last close | turned there three times · 2026-06-05 to 2026-08-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $3.24.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $3.24.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · lagging the market · Most volatile (6%+ typical daily range) · Stretched far below its 200-day average (6+ daily ranges) · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.29 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$5.92 range $3.50 – $13.00; median $4.50
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CVRX
- Consensus EPS estimate-$0.5029 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Commercialization execution risk: company expects to incur net losses for several years as it scales sales force and physician training while building market awareness and reimbursement coverage","Reimbursement dependency: 67% of target patients are Medicare-eligible; company relies on CMS coverage and prior authorization processes from multiple payers; loss of reimbursement coverage or unfavorable payment rates would significantly impact adoption","Supply chain concentration: multiple Barostim components sourced from limited suppliers with significant lead times; supply interruptions could constrain manufacturing and revenue growth"]
What changed in the latest 10-Q
AI-assisted comparison of CVRX's 10-Q filed 2026-05-12 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Added January 9, 2026 amendment to Loan Agreement increasing available term loans by $50.0 million to aggregate of $100.0 million with maturity extended to 2031 (filed 2026-05-12)
- Added disclosure of $60.0 million in outstanding Term Loans as of March 31, 2026 (filed 2026-05-12)
- Added new 'Recent developments' section detailing Category I CPT code transition effective January 1, 2026 (filed 2026-05-12)
- Added Medicare Advantage prior authorization approval rate data: 31% in 2024, 44% in 2025, 46% in Q1 2026 (filed 2026-05-12)
- Added November 2025 FDA grant of IDE study for BENEFIT-HF trial (filed 2026-05-12)
- Added January 2026 initiation of BENEFIT-HF trial with CMS Category B IDE coverage (filed 2026-05-12)
- Added details on BENEFIT-HF trial: prospective multi-center randomized controlled trial, ~150 centers, five-year enrollment, two-year follow-up, five to seven year conclusion (filed 2026-05-12)
- Added disclosure that first BENEFIT-HF site was activated on March 31, 2026 and first patient enrolled in Q2 2026 (filed 2026-05-12)
- Removed:
- Removed October 2025 CMS release of final 2026 Medicare Physician Fee Schedule discussion (filed 2025-11-06)
- Removed statement that 'We expect the transition to Category I will eliminate the automatic denials regularly seen with Category III codes' as forward-looking expectation language (filed 2025-11-06)
- Removed 'Factors affecting our performance' section listing six business impact factors (filed 2025-11-06)
- Removed 'Components of results of operations' section header and revenue discussion (filed 2025-11-06)
- Removed disclosure of $50.0 million in outstanding Term Loans as of September 30, 2025 (filed 2025-11-06)
- Reworded:
- Changed CPT code reference from 'Current Procedural Terminology codes' to 'Current Procedural Terminology ("CPT") codes' with added abbreviation (filed 2026-05-12)
- Changed spacing in NT-proBNP threshold from '< 1600' to '< 1,600' with comma (filed 2026-05-12)
- Reordered loan amendment disclosure to appear within main Overview section instead of 'Recent Developments' (filed 2026-05-12)
- Changed 'Recent Developments' description from expectation-focused language to actual results and milestones achieved (filed 2026-05-12)
- Notes:
- Older filing text appears truncated at end ('Cost of goods sold and gros'), limiting full comparison of subsequent sections
- Newer filing text also appears truncated mid-sentence in Amendment disclosure
Risk Factors
- Added:
- Newer filing (2026-05-12) adds two new exhibits: 10.1 Second Amendment to Loan and Security Agreement dated January 9, 2026, and 10.2 Form of Performance Stock Unit Agreement (Executives – 2026-2027 Cumulative Revenue)
- Newer filing (2026-05-12) expands Item 5 disclosure to include details about sell-to-cover arrangements for officers authorizing pre-arranged sales of shares to satisfy tax withholding obligations from RSU and PSU vesting, with language noting future events cannot be known
- Removed:
- Older filing (2025-11-06) contained a specific risk factor regarding Barostim's compliance with foreign governmental regulation in the European Economic Area under the EU Active Implantable Medical Devices Directive and MDR (Regulation EU 2017/745), including details about Notified Body requirements, clinical data requirements, and MDR compliance status as of April 9, 2025 - this entire risk factor is removed in newer filing
- Older filing (2025-11-06) stated 'Other than the risk factor set forth below, there have been no material changes to the risk factors' - this qualifying language is removed in newer filing
- Reworded:
- Item 1A Risk Factors header statement changed from 'Other than the risk factor set forth below, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K' in older filing (2025-11-06) to 'There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K' in newer filing (2026-05-12), with reference year changed from 2024 to 2025
- Item 5 disclosure changed from 'During the three months ended September 30, 2025, none of our directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement...' in older filing to 'During the three months ended March 31, 2026, none of our directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement..., except for certain sell-to-cover arrangements...' in newer filing (2026-05-12)
- Notes:
- The removal of the specific European regulatory risk factor in Item 1A corresponds with the statement that there have been no material changes to risk factors disclosed in the 10-K, suggesting that factor may have been disclosed in the Form 10-K for year ended December 31, 2025 rather than as a quarterly update
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 2 sells ($71322) — 2 selling insiders
Most recent open-market transaction: 2026-03-02. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CVRX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CVRX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,459,698
- Reported value $13,808,742
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CVRX had 2,009,524 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CVRX had 7.54% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.93 days to cover at the same settlement.
- Reported short interest (shares) 2,009,524
- Short interest (% of shares outstanding) 7.54%
- Prior settlement (shares) 1,926,164
- Reported change 4.33%
- Days to cover (reported) 7.93
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Abbott (ABT)
- Boston Scientific (BSX)
- Medtronic (MDT)
- LivaNova
- Cardiac neuromodulation devices
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CVRX vs…
Frequently asked questions
What does CVRX INC (CVRX) do?
CVRx is a commercial-stage medical device company developing and commercializing Barostim, an implantable neuromodulation device that delivers electrical pulses to baroreceptors in the carotid artery to treat heart failure with reduced ejection fraction (HFrEF). The device uses Baroreflex Activation Therapy (BAT) to modulate the autonomic nervous system and improve cardiovascular function in patients who have failed medical therapy. Barostim is FDA-approved in the U.S.
What sector is CVRX INC (CVRX) in?
CVRX INC (CVRX) is classified in the Health Care sector. Its industry is medical devices. It trades on NASDAQ.
Who are CVRX INC's (CVRX) competitors?
Notable peers of CVRX INC (CVRX) include Abbott, Boston Scientific, Medtronic, LivaNova and Cardiac neuromodulation devices. This peer set is informational only — not financial advice.
Is CVRX INC (CVRX) overbought or oversold right now?
CVRX INC (CVRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 34, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CVRX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.